Drug Trial Radar · NCT01287039
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
489
Actual
Start
Apr 2011
Primary completion
Dec 2013
Study completion Mar 2014
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.
Conditions
- Eosinophilic Asthma
Interventions
ReslizumabDrug
Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
PlaceboDrug
Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of TreatmentTime frame: Day 1 to Week 52
- Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)Time frame: Day 1 to Week 52
Locations
128 sites in 17 countries. Site status is shown where the registry gives one.
Teva Investigational Site 58
Scottsdale, Arizona
Teva Investigational Site 61
Los Angeles, California
Teva Investigational Site 37
Orange, California
Teva Investigational Site 56
San Diego, California
Teva Investigational Site 34
Colorado Springs, Colorado
Teva Investigational Site 52
DeBary, Florida
Teva Investigational Site 55
Miami, Florida
Teva Investigational Site 18
Valrico, Florida
Teva Investigational Site 49
Lexington, Kentucky
Teva Investigational Site 65
Louisville, Kentucky
Teva Investigational Site 51
Boston, Massachusetts
Teva Investigational Site 74
St Louis, Missouri
Teva Investigational Site 35
Missoula, Montana
Teva Investigational Site 64
Boys Town, Nebraska
Teva Investigational Site 68
Rochester, New York
Teva Investigational Site 60
The Bronx, New York
Teva Investigational Site 30
Winston-Salem, North Carolina
Teva Investigational Site 31
Cincinnati, Ohio
Teva Investigational Site 62
Columbus, Ohio
Teva Investigational Site 50
Oklahoma City, Oklahoma
Teva Investigational Site 66
Altoona, Pennsylvania
Teva Investigational Site 32
Nashville, Tennessee
Teva Investigational Site 63
Boerne, Texas
Teva Investigational Site 72
Houston, Texas
Teva Investigational Site 38
Richmond, Virginia
Teva Investigational Site 33
Madison, Wisconsin
Teva Investigational Site 641
Clayton, Australia
Teva Investigational Site 644
Daw Park, Australia
Teva Investigational Site 642
Frankston, Australia
Teva Investigational Site 645
Liverpool, Australia
Teva Investigational Site 643
Nedlands, Western Australia, Australia
Teva Investigational Site 261
Brussels, Belgium
Teva Investigational Site 264
Brussels, Belgium
Teva Investigational Site 260
Ghent, Belgium
Teva Investigational Site 262
Jambes, Belgium
Teva Investigational Site 263
Liège, Belgium
Teva Investigational Site 160
Rancagua, Chile
Teva Investigational Site 163
Santiago, Chile
Teva Investigational Site 164
Santiago, Chile
Teva Investigational Site 165
Santiago, Chile
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.